News

  • 10 January 2017

    Oxular Limited, the Oxford-based retinal therapeutics company, today announces the appointment of David Fellows, previously Non-Executive Director, as the Company’s Chairman of the Board. Mr. Fellows will replace Dr. Nigel Pitchford, who will continue on Oxular’s Board as a Director.

  • 5 January 2017

    Axonics Modulation Technologies, Inc. announced today that it received a Homologation d’un instrument médical (medical device approval) for the first rechargeable Sacral Neuromodulation (r-SNMTM) System® to treat Overactive Bladder (OAB), Fecal Incontinence and Urinary Retention.

  • 22 December 2016

    The Board of Directors of Sequana Medical AG ("Sequana Medical" or the "Company") announces with great sadness, the sudden death of its Founder, President and Chief Executive Officer, Noel L. Johnson, Ph. D.

  • 22 December 2016

    Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a biotechnology company developing innovative immunotherapies, and Genkyotex, a Swiss privately-held biopharmaceutical company and the leader in NOX therapies, announced today that Genticel has signed a contribution agreement with the shareholders of Genkyotex pursuant to which, subject to the approval of Genticel’s shareholders at a meeting expected to be held in the first quarter of 2017, Genkyotex’s shareholders will contribute in kind 100% of the Genkyotex share capital (on a fully diluted basis) to Genticel, which will issue new shares in remuneration for the contribution. Upon completion of the proposed transaction, Genkyotex’s shareholders will hold 80% of Genticel’s share capital and voting rights (on a non-diluted basis).

  • 12 December 2016

    Sonendo, Inc., the developer of a breakthrough technology for dentistry, announced today it has completed an equity financing totaling $35 million through new and existing investors.  The financing round led by DiNovA Capital will allow Sonendo to advance the commercialization of its GentleWave® System as an alternative to standard root canal treatment and develop additional products in adjacent verticals to leverage its Multisonic Ultracleaning™ technology platform.